Medical Advocates
Abacavir (Ziagen)
 
Journal Citations: Adult/
Adolescent

General Reports
 Dosage/Formulations
 Expanded Access
 Simplification Therapy
 Combination  Therapy
 Switching Therapies
 Management of Metabolic Disorders
 Dementia Management
 Salvage Therapy
 Discontinuation
 
Abacavir Main Page Main New/Newsworthy Home Page      
Last Updated:  October 24, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       
 
Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine: 96-Week
Results of a Randomized Study.
 Podzamczer D, Ferrer E, Sanchez P, et al 
J Acquir Immune Defic Syndr. 2006 Nov 9;
Abstract
 
Intracellular carbovir triphosphate levels in patients taking abacavir once a day.
Harris M,  Back G,  Kewn S, et al
 AIDS. 16(8):1196-1197, May 24, 2002
 Letter

FULL-TEXT ARTICLE
 HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and
efavirenz in treatment- experienced patients.
Falloon J, Ait-Khaled M, Thomas DA, et al.
AIDS 2002 Feb 15;16(3):387-396
 Paper

  
Dosage/Formulations
       
  Once-daily abacavir in place of twice-daily administration.
 Goedken AM, Herman RA.
Ann Pharmacother. 2005 Jul;39(7):1302-8.
Abstract		  
Expanded Access
       
  Abacavir expanded access program for adult patients infected with human
immunodeficiency virus type 1.
Kessler HA, Johnson J, Follansbee S, et al.
Clin Infect Dis 2002 Feb 15;34(4):535-42
Abstract		  
Treatment Simplification
       
  FULL-TEXT ARTICLE
Simplification with abacavir-based triple nucleoside therapy versus continued protease
inhibitor-based highly active  antiretroviral therapy in HIV-1-infected patients with
undetectable plasma HIV-1 RNA.
Clumeck N, Goebel F, Rozenbaum W, et al.
 AIDS 2001 Aug 17;15(12):1517-1526
 Paper		  
Combination Therapies
Epzicom Trizivir    
 
A WEEK-IN-REVIEW FEATURED REPORT
Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz,
Amprenavir/Ritonavir, or Stavudine.
 Bartlett JA, Johnson J, Herrera G, Sosa N, et al
 J Acquir Immune Defic Syndr. 2006 Sep 7;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a
Background Therapy Regimen of 2 Nucleoside Reverse-Transcriptase Inhibitors in Patients with
Initially Suppressed Viral Loads.
 Cozzi-Lepri A, Luca AD, Phillips AN, et al 
J Infect Dis. 2006 Jul 1;194(1):20-8.
 Abstract
 
The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a
substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable
plasma viral load.
 Bickel M, Rickerts V, Stephan C, et al 
HIV Med. 2005 May;6(3):179-84.
 Abstract
 
Pharmacokinetics and Pharmacodynamics of Low Dose Mycophenolate Mofetil in HIV-Infected
Patients Treated with Abacavir, Efavirenz and Nelfinavir.
 Millan O, Brunet M, Martorell J, et al  
Clin Pharmacokinet. 2005;44(5):525-38
 Abstract

FULL-TEXT PDF ARTICLE
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial
nucleoside/protease inhibitor-containing regimens.
 Swindells S, Cohen CJ, Berger DS, et al
 BMC Infect Dis. 2005 Apr 8;5(1):23
 Abstract

Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Therapy Containing
Once-Daily Abacavir, Lamivudine, and Tenofovir DF in Treatment-Naive HIV-Infected
Patients.
 Khanlou H, Yeh V, Guyer B, Farthing AC.
 AIDS Patient Care STDS. 2005 Mar;19(3):135-40.
 Abstract
 
Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and
Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults: Results
of the Ziagen Once Daily in Antiretroviral Combination Study.
 Moyle GJ, Dejesus E, Cahn P, et al 
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):417-425.
 Abstract
 
Body Composition and Metabolic Changes in Antiretroviral-Naive Patients Randomized to
Didanosine and Stavudine vs. Abacavir and Lamivudine.
 Shlay JC, Visnegarwala F, Bartsch G,et al
 J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):147-155
 Abstract
 
Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of
Antiretroviral-Naive HIV-Infected Adults.
Dejesus E, Herrera G, Teofilo E, et al
Clin Infect Dis. 2004 Oct 1;39(7):1038-46.
 Abstract
 
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet
(COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week
open-label, equivalence trial (CNA3014).
 Vibhagool A, Cahn P, Schechter M, et al 
Curr Med Res Opin. 2004 Jul;20(7):1103-14.
 Abstract
 
FULL-TEXT ARTICLE
Low efficacy and high frequency of adverse events in a randomized trial of the
triple nucleoside regimen abacavir, stavudine and didanosine.
Gerstoft J, Kirk O, Obel N, et al 
AIDS. 2003 Sep 26;17(14):2045-2052.
 Paper
Abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active
antiretroviral therapy in HIV-1-positive patients.
Diego R, Franco M, Claudio A, Fredy S
AIDS. 16(14):1981, September 27, 2002.
Letter

Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic
inhibition in combination with abacavr, didanosine, and tenofovir.
 Hossain MM, Coull JJ, Drusano GL, Margolis DM.
Antiviral Res 2002 Jul;55(1):41-52

FULL-TEXT PDF ARTICLE
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
Recommendations of the Panel on Clinical Practices for Treatment of HIV.
 MMWR Morb Mortal Wkly Rep. 2002 May 17;51(RR-7):1-55.
 Paper

FULL-TEXT ARTICLE
 Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in
Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults 
McDowell JA, Lou Y, Symonds WS, Stein DS.
Antimicrob. Agents Chemother. 2000 44: 2061-2067
 Paper
 
FULL-TEXT ARTICLE
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a
randomized, double-blind, trial.
Katlama C, Clotet B, Plettenberg A, et al
 AIDS. 14(7):781-789, May 5, 2000.
Paper

 
Switching Therapies
       
  A WEEK-IN-REVIEW FEATURED REPORT
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful
first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing
efavirenz, nevirapine, or abacavir.
 Abgrall S, Yeni PG, Bouchaud O, et al
Clin Infect Dis. 2007 Jan 1;44(1):120-7.
 Abstract
 
  A WEEK-IN-REVIEW FEATURED REPORT
Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated
with suboptimal antiretroviral therapy: A review.
 Rizzardini G, Capetti A
Med Sci Monit. 2006 Nov 23;12(12):RA269-276
 Abstract
Management of Metabolic Disorders
       
 
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or
nevirapine.
 Fisac C, Fumero E, Crespo M, et al
AIDS. 2005 Jun 10;19(9):917-925
 Abstract
 
Increased Adipocyte Apoptosis in Lipoatrophy Improves Within 48 Weeks of Switching Patient
Therapy From Stavudine to Abacavir or Zidovudine.
 Cherry CL, Lal L, Thompson KA, et al 
J  Acquir Immune Defic Syndr. 2005 Mar 1;38(3):263-267. |
 Abstract
 
FULL-TEXT ARTICLE
 Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens
improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
 Keiser PH, Sension MG, Dejesus, E, et al 
BMC Infect Dis. 2005 Jan 12;5(1):2
 Paper
 
Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing
stavudine with abacavir or zidovudine.
 McComsey GA, Paulsen DM, Lonergan JT  
AIDS. 2005 Jan 3;19(1I):15-23.
 Abstract
 
Lack of Recurrence of Hyperlactatemia in HIV-Infected Patients Switched From Stavudine to
Abacavir or Zidovudine.
 The ESS40010 (TARHEEL) Study Team.
J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):935-942.
 Abstract|
 
FULL-TEXT ARTICLE
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine
analogue to abacavir: the MITOX Extension Study.
 For the Mitochondrial Toxicity (MITOX) Study Group.
AIDS. 2004 Apr 20;18(7):1029-1036.
 Paper
 
Changes in Mitochondrial DNA in Peripheral Blood Mononuclear Cells from HIV-Infected
Patients with Lipoatrophy Randomized to Receive Abacavir.
 Hoy JF, Gahan ME, Carr A, et al
 J Infect Dis. 2004 Aug 15;190(4):688-92
 Abstract

Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy:
A Randomized Trial.
 Carr A, Workman C, Smith DE, et al.
JAMA 2002 Jul 10;288(2):207-15
 Abstract
 
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human
immunodeficiency virus-infected patients switched from stavudine to abacavir or
zidovudine: the results of the TARHEEL study.
 McComsey GA, Ward DJ, Hessenthaler SM, et al.  
Clin Infect Dis. 2004 Jan 15;38(2):263-70
 Abstract
 
Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy.
Garcia-Benayas T, Blanco F, de la Cruz J, et al
AIDS. 17(6):921-924, April 11, 2003.
 Latter

Improvement of HAART-associated insulin resistance and dyslipidemia after replacement
of protease inhibitors with abacavir.
Walli RK, Michl GM, Bogner JR, Goebel FD.
Eur J Med Res 2001 Oct 29;6(10):413-21
 Abstract

  
Management of AIDS Dementia
       
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL TEXT ARTICLE
 Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial
 Brew BJ, Halman M, Catalan J, et al
PLoS Clin Trials. 2007 Mar 30;2(3):e13
Paper

FULL-TEXT ARTICLE
HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with
AIDS dementia complex treated with Abacavir.
Lanier ER, Sturge G, McClernon D, et al
AIDS 2001 Apr 13;15(6):747-51
 Paper

  
Salvage Therapy
       
  Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir
and efavirenz salvage regimen.
 Vallejo A, Olivera M, Rubio A, et al.
Antiviral Res. 2004 Feb;61(2):129-32
 Abstract
 
FULL-TEXT ARTICLE
Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a
protease inhibitor in heavily pre-treated HIV-1 infected patients.
Khanna N, Klimkait Y, Schiffer V, et al
AIDS. 14(7):791-799, May 5, 2000.
 Paper
 
 Discontinuation
       
 
An analysis fo causes for the discontinuation of a simplified antiretroviral regimen with
abacavir, lamivudine and zidovudine.
 Morillo Verdugo R, Abdel-Kader Martin L
Farm Hosp. 2005 Jul;29(3):164-70.
 Abstract

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients.
Peyriere H, Guillemin V, Lotthe A, et al 
Ann Pharmacother. 2003 Oct;37(10):1392-7.
 Abstract

Abacavir Main Page Main New/Newsworthy Home Page      

Abacavir Journal Papers, Abstracts, and Commentaries